IDRA-21 is one of the newer nootropic compounds available in the market today. It belongs to the ampakine family. Ampakines are compounds acting as facilitators of improved attention and learning ability through activating AMPA glutamate receptor. Its nootropic potential are currently being evaluated by scientists and experts in the field for the treatment of cognitive deficits. IDRA-21 features excellent benefits which primarily includes cognitive functioning improvement .
IDRA-21 is one of the newer nootropic compounds available in the market today. It belongs to the ampakine family. Ampakines are compounds acting as facilitators of improved attention and learning ability through activating AMPA glutamate receptor. Its nootropic potential are currently being evaluated by scientists and experts in the field for the treatment of cognitive deficits. IDRA-21 features excellent benefits which primarily includes cognitive functioning improvement .Key Findings
Some key findings on studies evaluating the effects of IDRA-21 include:
- Improvement of cognitive functioning    
- Treat memory and cognitive disorders such as Alzheimer’s disease  
- Improve memory and overall cognitive function amongst the aging population 
- Promotes neurological beneficial effects without causing neurotoxicity. It is relatively safe to use when administered on therapeutic doses 
Please note: This article is for informational purposes only. Only buy IDRA-21 for research. We do not encourage intake of IDRA-21 or any other nootropic substance listed/discussed/sold on this site.
The primary benefit associated with IDRA-21 administration includes improved cognitive functioning. This effect was epitomized in a clinical trial subjecting patas monkeys to alprazolam-induced learning deficit. Patas monkeys demonstrated huge decreases in accuracy and response rate while under the influence of alprazolam. Administration of IDRA-21 and aniracetam has antagonized these effects whereas learning deficits elicited by the alprazolam were greatly reduced. This study revealed that IDRA-21 antagonized the desensitization of AMPA receptors . Another study involving rats elicited similar positive results. Oral administration of IDRA-21 was revealed to enhance performance of rat subjects after being exposed to a water maze cognition test .
One study demonstrated IDRA-21’s ability to treat memory and cognitive disorders associated with aging. In this particular study, the performance of aged and young rhesus monkeys administered with IDRA-21 was evaluated during a delayed matching to sample task. The result of this test revealed that IDRA-21 improved performance levels of the aged rhesus as compared to the young ones indicating that it may be more effective when administered to aged patients .
A clinical trial comparing the effects of huperzine A and IDRA-21 revealed results in favor of the latter compound. This study involved the administration of huperzine A and IDRA-21 amongst 6 young macaques. The macaques were trained on performing a delayed non-matching to sample task. The administration of huperzine A was discovered to decrease baseline performance while IDRA-21 promoted enhancement on this task. Henceforth, IDRA-21 may be a potent drug for improving cognitive and memory problems such as those seen in Alzheimer’s disease .
What makes IDRA-21 a truly novel nootropic drug include its ability to promote these effects without causing any notable undesirable effects. Studies have shown that despite promoting improved cognitive functioning, IDRA-21 promote notable desensitization of AMPA receptor without causing neurotoxicity . It has also not caused undesirable effects on subjects of most studies evaluating its effects . However, therapeutic doses must be observed as it may promote ischemic neuronal injury in the hippocampus when used in excessive amounts .
How does IDRA-21 work and why you should buy IDRA-21?
IDRA-21 is categorized under the ampakine class of nootropics. Ampakines are popular as modulators of the crucial glutamatergic AMPA receptors in the brain. Simply put it, ampakines bind to brain receptors that promotes excitatory responses such as improved attention, responsiveness and alertness. Ampakines also enhances the influence of neurotransmitters that normally bind to them – one of which includes glutamate. Hence, IDRA-21 has the ability to decrease glutamate receptor desensitization  .
Note that glutamate alongside gamma amino butyric acid (GABA) is a crucial neurotransmitter for optimal cognitive functioning. Glutamate is considered as the most powerful excitatory neurotransmitter in the central nervous system responsible for improving reasoning, deduction, attention span, quick response and wakefulness. However, excessive glutamate activity could cause undesirable effects such as jitteriness, overstimulation, anxiety and nervousness. Glutamate deficiency on the other hand could cause disinterestedness, slow responses, decreased cognitive function and lack of motivation  .
GABA on the other hand is considered as the most powerful inhibitory neurotransmitter in the central nervous system. It is responsible for relaxation, calmness and relief from anxiety. Nonetheless, excessive activity may cause destructive cognitive problems including impaired reasoning, depression, and decreased reaction time. GABA deficiency is also undesirable as it may cause anxiety, nervousness and stress. Therefore, maintaining proper balance of GABA and glutamate is crucial  . IDRA-21 has the ability to maintain this balance. It represents a prototype enhancing cognitive functioning through acting as a potent inhibitor of agonist dependent AMPA receptor desensitization while having limited intrinsic activity . Conclusively, it prevents excessive as well as decreased glutamate and GABA activity that negatively influence cognitive behaviors.